Fluconazole and Amphotericin B Comparison in Acute Cryptococcal Meningitis Treatment
Flucytosine
+ Fluconazole
+ Amphotericin B
Blood-Borne Infections+26
+ Neuroinflammatory Diseases
+ Urogenital Diseases
Treatment Study
Summary
This study focuses on comparing two treatments for acute cryptococcal meningitis, a serious infection that causes inflammation in the membranes surrounding the brain. The two treatments are fluconazole (UK-49,858) and amphotericin B, which may also be used in combination with another drug called flucytosine. The goal is to determine which treatment works better and is safer for individuals affected by this condition. This research is important as it aims to improve the care and treatment options for those suffering from acute cryptococcal meningitis. During the study, participants receive either fluconazole or amphotericin B, potentially along with flucytosine. The effectiveness and safety of these treatments are then evaluated. The study measures how well each treatment works in managing the infection and reducing its symptoms, as well as any potential side effects. The results of this study could provide valuable insights into the best treatment strategies for acute cryptococcal meningitis.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Concurrent Medication: Allowed: Immunosuppressant therapy. Antiviral therapy such as zidovudine. Prophylaxis for Pneumocystis carinii pneumonia. Concurrent Treatment: Allowed: Radiation therapy for mucocutaneous Kaposi's sarcoma. Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian. No prior systemic antifungal therapy for cryptococcosis. Relapse after prior therapy. Success of prior therapy must have been documented by negative cerebrospinal fluid (CSF) culture at the end of therapy. Following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into study. Prior Medication: Allowed: Immunosuppressant therapy. Antiviral therapy (such as zidovudine). Prophylaxis for Pneumocystis carinii pneumonia. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. History of allergy to or intolerance of imidazoles, azoles, or amphotericin B. Moderate or severe liver disease. Comatose. Unlikely to survive more than 2 weeks. Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research. Concurrent Medication: Excluded: Coumadin-type anticoagulants. Oral hypoglycemics. Barbiturates. Phenytoin. Immunostimulants. Investigational drugs or approved (licensed) drugs for investigational indications. Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research. Excluded within 4 weeks of study entry: Greater than 1 mg/kg/wk amphotericin B. Concurrent Treatment: Excluded: Lymphocyte replacement. Patients with the following are excluded: Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. History of allergy to or intolerance of imidazoles, azoles, or amphotericin B. Moderate or severe liver disease. Comatose. Unlikely to survive more than 2 weeks. Prior Medication: Excluded: Coumadin-type anticoagulants. Oral hypoglycemics. Barbiturates. Phenytoin. Immunostimulants. Investigational drugs or approved (licensed) drugs for investigational indications. Excluded within 4 weeks of study entry: Greater than 1 mg/kg/wk amphotericin B. Prior Treatment: Excluded: Lymphocyte replacement.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 45 locations
Univ of Alabama at Birmingham
Birmingham, United StatesOpen Univ of Alabama at Birmingham in Google MapsTucson Veterans Administration Med Ctr
Tucson, United StatesUCLA CARE Ctr
Los Angeles, United StatesDr Shelly Gordon
San Francisco, United States